Quadruple rescue terapy afer first and second line failure for Helicobacter pylori treatment: Comparison between two tetracycline-based regimens

Journal of Gastrointestinal and Liver Diseases

Volumn 23, Issue 4, 2014, Pages 367-370

  Ierardi, Enzo ^a   Giangaspero, Antonio ^a   Losurdo, Giuseppe ^a   Giorgio, Floriana ^a   Amoruso, Annacinzia ^a   De Francesco, Vincenzo ^a,b   Di Leo, Alfredo ^a   Principi, Mariabeatrice ^a  

^a UNIVERSITY OF BARI   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Antibiotic resistance; Helicobacter pylori; Minocycline; Rescue therapy; Rifabutin

Indexed keywords

BISMUTH CITRATE; MINOCYCLINE; PREBIOTIC AGENT; RABEPRAZOLE; RIFABUTIN; TINIDAZOLE; ANTIINFECTIVE AGENT; ORGANOMETALLIC COMPOUND; PROTON PUMP INHIBITOR;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; ASTHENIA; BACTERIAL CLEARANCE; CLINICAL TRIAL (TOPIC); DIARRHEA; DYSPEPSIA; ENDOSCOPY; FECES ANALYSIS; FEMALE; HELICOBACTER INFECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; UREA BREATH TEST; BREATH ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECTS; FECES; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; ITALY; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; TIME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BREATH TESTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; FECES; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ITALY; MALE; MIDDLE AGED; MINOCYCLINE; ORGANOMETALLIC COMPOUNDS; PROTON PUMP INHIBITORS; RABEPRAZOLE; RIFABUTIN; TIME FACTORS; TINIDAZOLE; TREATMENT FAILURE; YOUNG ADULT;

EID: 84914691547     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol 2013;19:8168-8180.
2. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646-664.
3. Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol 2014;20:1517-1528.
4. Fiorini G, Vakil N, Zullo A, et al. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2013;11:507-510.
5. Caselli M, Zullo A, Maconi G, et al. „Cervia II Working Group Report 2006”: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007;39:782-789.
6. Gisbert J P, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ter 2012;35:209-221.
7. Cianci R, Montalto M, Pandolf F, Gasbarrini GB, Cammarota G. Tird-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol 2006;12:2313-2319.
8. Ierardi E, Goni E, Losurdo G, Di Mario F. Helicobacter pylori and nonmalignant diseases. Helicobacter 2014;19 Suppl 1:27-31.
9. Venerito M, Nardone G, Selgrad M, Rokkas T, Malfertheiner P. Gastric cancer--epidemiologic and clinical aspects. Helicobacter 2014;19 Suppl 1:32-37.
10. O’Connor A, Taneike I, Nami A, et al. Helicobacter pylori resistance rates for levofoxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Ir J Med Sci 2013;182:693-695.
11. Brogden RN, Fitton A. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efcacy. Drugs 1994;47:983-1009.
12. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-414.
13. Murakami K, Sato R, Okimoto T, et al. Efectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2006;21:262-267.
14. Nakajima S, Inoue H, Inoue T, Maruoka Y. Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy. J Gastroenterol Hepatol 2012;27 Suppl 3:108-111.
15. Gisbert J P, Perez-Aisa A, Rodrigo L, et al Tird-line rescue therapy with bismuth-containing quadruple regimen afer failure of two treatments (with clarithromycin and levofoxacin) for H. pylori infection. Dig Dis Sci 2014;59:383-389.
16. Gomollón F, Sicilia B, Ducóns JA, Sierra E, Revillo MJ, Ferrero M. Tird line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ter 2000;14:1335-1338.
17. U S Food and Drug Administration. www.fda.gov/
18. European Medicines Agency. www.ema.europa.eu/
19. Seo JH, Jun JS, Yeom JS, et al. Changing pattern of antibiotic resistance of Helicobacter pylori in children during 20 years in Jinju, South Korea. Pediatr Int 2013;55:332-336.
20. Tan Y, Hu Z, Zhao Y, et al. Te beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. J Clin Microbiol 2012;50:81-85.
21. Miyazaki M, Nagata N, Matsuo K, Takata T, Tanihara S, Kamimura H. Trends and antimicrobial susceptibilities of clinical methicillin-resistant Staphylococcus aureus isolates in Fukuoka University Chikushi Hospital 2008-2012. Yakugaku Zasshi 2014;134:269-276.
22. Kanj SS, Whitelaw A, Dowzicky MJ. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011. Int J Antimicrob Agents 2014;43:170-178.
23. Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ter 2006;24:395-403.
24. Grifth DE, Brown BA, Girard WM, Wallace RJ Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-598.